Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT04811027 |
| Title | Combination Study With Eftilagimod Alpha (a Soluble LAG-3 Fusion Protein) and Pembrolizumab in Patients With Recurrent or Metastatic HNSCC (TACTI-003) |
| Acronym | TACTI-003 |
| Recruitment | Active, not recruiting |
| Gender | both |
| Phase | Phase II |
| Variant Requirements | No |
| Sponsors | Immutep S.A.S. |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | USA | ROU | GBR | ESP | DNK | DEU | BEL | AUS |